Literature DB >> 24732892

Effects of cardiac overexpression of the angiotensin II type 2 receptor on remodeling and dysfunction in mice post-myocardial infarction.

Jiang Xu1, Ying Sun, Oscar A Carretero, Liping Zhu, Pamela Harding, Edward G Shesely, Xiangguo Dai, Nour-Eddine Rhaleb, Edward Peterson, Xiao-Ping Yang.   

Abstract

The activation of angiotensin II type 2 receptor (AT2R) has been considered cardioprotective. However, there are controversial findings regarding the role of overexpressing AT2R in the heart. Using transgenic mice with different levels of AT2R gene overexpression in the heart (1, 4, or 9 copies of the AT2R transgene: Tg1, Tg4, or Tg9), we studied the effect of AT2R overexpression on left ventricular remodeling and dysfunction post-myocardial infarction (MI). Tg1, Tg4, Tg9, and their wild-type littermates were divided into (1) sham MI, (2) MI plus vehicle, and (3) MI plus AT2R antagonist. Treatments were started 4 weeks after MI and continued for 8 weeks. AT2R protein and mRNA expression in the heart was significantly increased in transgenic mice, and the increase positively correlated with copies of the transgene. AT1R protein and mRNA expression remained unchanged in Tg1 and Tg4 but slightly increased in Tg9 mice. Systolic blood pressure and cardiac phenotypes did not differ among strains under basal conditions. MI caused myocardial hypertrophy, interstitial fibrosis, ventricular dilatation, and dysfunction associated with increased protein expression of Nox2 and transforming growth factor β1. These pathological responses were diminished in Tg1 and Tg4 mice. Moreover, the protective effects of AT2R were abolished by AT2R antagonist and also absent in Tg9 mice. We thus conclude that whether overexpression of AT2R is beneficial or detrimental to the heart is largely dependent on expression levels and possibly via regulations of Nox2 and transforming growth factor β1 signaling pathways.

Entities:  

Keywords:  mice, transgenic; myocardial infarction; receptor, angiotensin, type 1; receptor, angiotensin, type 2

Mesh:

Substances:

Year:  2014        PMID: 24732892      PMCID: PMC4031246          DOI: 10.1161/HYPERTENSIONAHA.114.03247

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

1.  Angiotensin II AT2 receptor localization in cardiovascular tissues by its antibody developed in AT2 gene-deleted mice.

Authors:  Hirotoshi Utsunomiya; Misa Nakamura; Kennichi Kakudo; Tadashi Inagami; Masaaki Tamura
Journal:  Regul Pept       Date:  2005-03-30

Review 2.  Role of transforming growth factor-beta in the progression of heart failure.

Authors:  H Lim; Y Z Zhu
Journal:  Cell Mol Life Sci       Date:  2006-11       Impact factor: 9.261

3.  Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.

Authors:  Masaru Iwai; Rui Chen; Zhen Li; Tetsuya Shiuchi; Jun Suzuki; Ayumi Ide; Masahiro Tsuda; Midori Okumura; Li-Juan Min; Masaki Mogi; Masatsugu Horiuchi
Journal:  Circulation       Date:  2005-09-06       Impact factor: 29.690

4.  AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.

Authors:  Yoshihiko Oishi; Ryoji Ozono; Masao Yoshizumi; Masahiro Akishita; Masatsugu Horiuchi; Tetsuya Oshima
Journal:  Life Sci       Date:  2006-09-06       Impact factor: 5.037

5.  The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.

Authors:  Angelo D'Amore; M Jane Black; Walter G Thomas
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

6.  Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects.

Authors:  H Masaki; T Kurihara; A Yamaki; N Inomata; Y Nozawa; Y Mori; S Murasawa; K Kizima; K Maruyama; M Horiuchi; V J Dzau; H Takahashi; T Iwasaka; M Inada; H Matsubara
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

7.  Differential distribution of angiotensin AT2 receptors in the normal and failing human heart.

Authors:  J Wharton; K Morgan; R A Rutherford; J D Catravas; A Chester; B F Whitehead; M R De Leval; M H Yacoub; J M Polak
Journal:  J Pharmacol Exp Ther       Date:  1998-01       Impact factor: 4.030

8.  Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction.

Authors:  Masaharu Nakayama; Xinhua Yan; Robert L Price; Thomas K Borg; Kenta Ito; Atsushi Sanbe; Jeffrey Robbins; Beverly H Lorell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09-16       Impact factor: 4.733

9.  Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction.

Authors:  Jiang Xu; Oscar A Carretero; Chun-Xia Lin; Maria A Cavasin; Edward G Shesely; James J Yang; Timothy L Reudelhuber; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-06-22       Impact factor: 4.733

Review 10.  Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide.

Authors:  Katsutoshi Yayama; Hiroshi Okamoto
Journal:  Int Immunopharmacol       Date:  2007-07-19       Impact factor: 4.932

View more
  14 in total

Review 1.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

2.  Overexpression of angiotensin II type 2 receptor promotes apoptosis and impairs insulin secretion in rat insulinoma cells.

Authors:  Min Liu; Danqing Jing; Yan Wang; Yu Liu; Shinan Yin
Journal:  Mol Cell Biochem       Date:  2014-11-28       Impact factor: 3.396

3.  MiR-126 Affects Brain-Heart Interaction after Cerebral Ischemic Stroke.

Authors:  Jieli Chen; Chengcheng Cui; Xiaoping Yang; Jiang Xu; Poornima Venkat; Alex Zacharek; Peng Yu; Michael Chopp
Journal:  Transl Stroke Res       Date:  2017-01-19       Impact factor: 6.829

Review 4.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 5.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

6.  Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction.

Authors:  Alexander Sirker; Colin E Murdoch; Andrea Protti; Greta J Sawyer; Celio X C Santos; Daniel Martin; Xiaohong Zhang; Alison C Brewer; Min Zhang; Ajay M Shah
Journal:  J Mol Cell Cardiol       Date:  2016-07-07       Impact factor: 5.000

Review 7.  Anti-fibrotic Potential of AT2 Receptor Agonists.

Authors:  Yan Wang; Mark Del Borgo; Huey W Lee; Dhaniel Baraldi; Baydaa Hirmiz; Tracey A Gaspari; Kate M Denton; Marie-Isabel Aguilar; Chrishan S Samuel; Robert E Widdop
Journal:  Front Pharmacol       Date:  2017-08-31       Impact factor: 5.810

8.  c-kit(+)AT2R(+) Bone Marrow Mononuclear Cell Subset Is a Superior Subset for Cardiac Protection after Myocardial Infarction.

Authors:  Mingjun Du; Sebastian Schmull; Wentian Zhang; Chenxi Wang; Feng Lian; Yao Chen; Song Xue
Journal:  Stem Cells Int       Date:  2016-06-27       Impact factor: 5.443

9.  Erythropoietin alleviates post-resuscitation myocardial dysfunction in rats potentially through increasing the expression of angiotensin II receptor type 2 in myocardial tissues.

Authors:  Hourong Zhou; Jia Huang; Li Zhu; Yu Cao
Journal:  Mol Med Rep       Date:  2018-01-24       Impact factor: 2.952

10.  Withaferin A attenuates ovarian cancer-induced cardiac cachexia.

Authors:  Natia Q Kelm; Alex R Straughn; Sham S Kakar
Journal:  PLoS One       Date:  2020-07-28       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.